Treatment of AGK2, a selective inhibitor of SIRT2, blocked the therapeutic action of NR against NAFLD pathologies and NR-induced Fndc5 deubiquitination/deacetylation. This evidence concerns the gene SIRT2 and metabolic dysfunction-associated steatotic liver disease.